Resmed’s high margin and recurrent-revenue segment are the core attractions of its business. On margins, the outlook is positive Resmed’s improved update on sales costs and a proposed reduction in headcount. The impact of GLP-1 drugs on the sleep disorder device industry are overly pessimistic, but could deliver continued short term pain as the market factor in their impacts.
Resmed’s high margin and recurrent-revenue segment are the core...
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$32.80 |
Change
0.370(1.14%) |
Mkt cap ! $20.92B | |||
| Open | High | Low | Value | Volume |
| $32.65 | $32.90 | $32.61 | $56.44M | 1.720M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1166 | $32.79 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $32.80 | 2532 | 2 |
View Market Depth
| Last trade - 16.10pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$32.81 |
Change
0.370 ( 1.22 %) |
||||
| Open | High | Low | Volume | ||
| $32.62 | $32.89 | $32.62 | 168153 | ||
| Last updated 15.59pm 21/05/2024 ? | |||||
| RMD (ASX) Chart |